Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Background: In the global ARASENS study (NCT02799602), darolutamide plus androgen-deprivation therapy (ADT) and docetaxel significantly reduced risk of death by 32.5% versus placebo plus ADT and docetaxel (hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.

Predicting radiotoxic effects after BNCT for brain cancer using a novel dose calculation model.

Purpose: The normal brain is an important dose-limiting organ for brain cancer patients undergoing radiotherapy. This study aims to develop a model to calculate photon isoeffective doses (D) to normal brain that can explain the incidence of grade 2 or higher somnolence syndrome (SS⩾2) after Boron Neutron Capture Therapy (BNCT).

Methods: A D model was constructed to find the reference photon dose that equals the Normal Tissue Complication Probability (NTCP) of the absorbed dose from BNCT.